Pharmaceutical

‘We fail people’: New data on disparities in Medicaid a...

Overall, the study found that 55% of Medicaid enrollees with opioid addiction re...

STAT+: Pharmalittle: FDA approves first gene therapy fo...

The states of California, New York, Illinois, Minnesota, Washington, and Wiscons...

STAT+: EU poised to reject Amylyx’s ALS drug, as the co...

European regulators are on the verge of rejecting an ALS drug from Amylyx Pharma...

STAT+: GSK settles first lawsuit set for a U.S. trial o...

GSK reached a settlement with a man who claimed its Zantac heartburn medication ...

Biden directs HHS to boost contraception access, a year...

The president’s executive order instructs HHS to ensure people on commercial ins...

How a six-in-one vaccine could soon help the world get ...

A new vaccine could increase the number of children around the world who are pro...

STAT+: Using its Covid know-how, Color Health aims to m...

Frictionless cancer screening? Color Health, a health tech company known for its...

STAT+: At a defunct power station, the U.K. and Moderna...

At a defunct power station, the U.K. and Moderna celebrate a partnership meant t...

Opinion: The staggering financial burden of giving birt...

Privately insured families pay on average about $3,000 for maternal and newborn ...

New research underscores benefits of gender-affirming h...

“It's very motivating to me to actually provide the evidence to show the benefit...

Opinion: OB-GYNs could have solidified abortion as heal...

If 50 years ago the field of OB-GYN had not been so skittish about abortion, thi...

Intercept winds down NASH programme after FDA pulls plu...

The FDA has blocked the approval of Intercept’s NASH therapy, pushing the compan...

MSD extends peptide collaboration with IRBM

IRBM has extended its collaboration with MSD to develop peptide therapeutics, fo...

FDA approves Duchenne gene therapy with hefty $3.2m pri...

Sarepta will now need to complete a confirmatory trial to prove the therapy impr...

NephroDI Therapeutics and MSRD partner to develop thera...

NephroDI Therapeutics has signed a deal with the McQuade Center for Strategic Re...

BMS and Eurofins invest in Indian pharma hubs Andhra Pr...

Facilities in Andhra Pradesh and Telangana accounted for 23% of all sites in Ind...